|Mr. Eddie Gray||CEO & Director||602k||N/A||1959|
|Dr. Dennis A. Carson||Co-Founder & Director||40k||N/A||1947|
|Mr. Michael S. Ostrach||CFO, Chief Bus. Officer & Sr. VP||427k||N/A||1952|
|Mr. David F. Novack||Sr. VP of Operations and Quality||388.25k||N/A||1962|
|Dr. Robert L. Coffman||Chief Scientific Officer and Sr. VP||468.8k||N/A||1947|
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Dynavax Technologies Corporation’s ISS Governance QualityScore as of April 1, 2018 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 9; Compensation: 9.